Clinical Trial

Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

Study acronym: TEC-CARE
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
200 adult patients with multiple myeloma receiving teclistamb will be included. Effectiveness, safety, and condition of use of teclistamab in early access program (post-MA) will be assessed. Primary objective is the evaluation of overall response rate (ORR) of teclistamab according to IMWG criteria. This is a multicenter, prospective, observational study.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-09-28; most recent amendment 2026-04-08.
Status change: Recruiting → Active, Not Recruiting 2025-05-20
Trial Details
NCT Number NCT06062537
Lead Sponsor Intergroupe Francophone du Myelome
Collaborators: Janssen-Cilag Ltd.
Conditions Multiple Myeloma
Enrollment 200 participants
Start Date 2023-09-19
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-13